Apricus Biosciences (NASDAQ: APRI) and Corium International (NASDAQ:CORI) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Profitability

This table compares Apricus Biosciences and Corium International’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Apricus Biosciences N/A N/A -139.67%
Corium International -145.60% -673.17% -61.19%

Valuation & Earnings

This table compares Apricus Biosciences and Corium International’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Apricus Biosciences $5.76 million 4.15 -$7.43 million $0.58 2.71
Corium International $33.02 million 12.13 -$36.70 million ($1.73) -6.48

Apricus Biosciences has higher revenue, but lower earnings than Corium International. Corium International is trading at a lower price-to-earnings ratio than Apricus Biosciences, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

15.3% of Apricus Biosciences shares are owned by institutional investors. Comparatively, 90.1% of Corium International shares are owned by institutional investors. 3.6% of Apricus Biosciences shares are owned by company insiders. Comparatively, 46.5% of Corium International shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Apricus Biosciences has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Comparatively, Corium International has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Apricus Biosciences and Corium International, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Apricus Biosciences 0 0 2 0 3.00
Corium International 0 0 7 0 3.00

Apricus Biosciences presently has a consensus target price of $4.50, indicating a potential upside of 186.62%. Corium International has a consensus target price of $13.14, indicating a potential upside of 17.24%. Given Apricus Biosciences’ higher possible upside, equities analysts plainly believe Apricus Biosciences is more favorable than Corium International.

Summary

Corium International beats Apricus Biosciences on 7 of the 12 factors compared between the two stocks.

Apricus Biosciences Company Profile

Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT. The Company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud’s phenomenon, secondary to scleroderma. The Company has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe.

Corium International Company Profile

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.

Receive News & Ratings for Apricus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.